SCHEMBL629669

SCHEMBL629669

O=C(O)Cc1cccc(-c2ccc3cc(OCc4ccccc4)c(N4CC(=O)NS4(=O)=O)cc3c2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 5/20 0.49
CFD P00746 5/20 0.39
F11 P03951 5/20 0.39
TPSB2 P20231 3/20 0.39
KLKB1 P03952 2/20 0.39
PLG P00747 1/20 0.39
PLAU P00749 1/20 0.39
F7 P08709 1/20 0.39
PPARD Q03181 4/20 0.38
PPARA Q07869 1/20 0.38
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2B Q13224 1/20 0.38
GRIN2C Q14957 1/20 0.38
GRIN3A Q8TCU5 1/20 0.38
FFAR1 O14842 3/20 0.38
PTGER1 P34995 2/20 0.38
PTGER4 P35408 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL629597 0.90 PTPN1 (0.47) PTPN1CFDPPARDFFAR1ENPP2
SCHEMBL630626 0.89 PTPN1 (0.51) PTPN1CFDF11TPSB2KLKB1
SCHEMBL629847 0.87 PTPN1 (0.49) PTPN1PPARDFFAR1
SCHEMBL630121 0.85 PTPN1 (0.56) PTPN1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL631155 0.85 PTPN1 (0.51) PTPN1PPARDFFAR1PTGER1
SCHEMBL4646708 0.83 PTPN1 (0.60) PTPN1PPARDPTGER1PTGER4PTGER3
Potassium SCHEMBL629775 0.82 PTPN1 (0.51) PTPN1
SCHEMBL629774 0.82 PTPN1 (0.51) PTPN1
SCHEMBL629591 0.81 PTPN1 (0.46) PTPN1
SCHEMBL3006427 0.81 PTPN1 (0.46) PTPN1PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963292-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2012-02-22 EP disclosed
US-7700633-B2 Organic compounds NOVARTIS AG (CH) 2010-04-20 US disclosed
US-20080262050-A1 Organic Compounds NOVARTIS AG (CH) 2008-10-23 US disclosed
EP-1963292-A2 ORGANIC COMPOUNDS Novartis Pharma AG (CH) 2008-09-03 EP disclosed
WO-2007067615-A2 THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262050-A1 Organic Compounds PTPRS, PTPRO, PTPRC PTPN1 23/4885CFD 4819/4885F11 4430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.